The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The Phase 3 EPCORE DLBCL-4 trial showed that the epcoritamab combination reduced the risk of disease progression by up to 60% in relapsed/refractory DLBCL. Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide, demonstrating a statistically significant improvement in progression-free survival. AbbVie also announced a Phase 3 victory for epcoritamab in relapsed/refractory DLBCL, meeting its primary endpoint.